SCHEDULE: State Street Corp. Discloses Stake in Capricor Therapeutics

State Street Corporation has reported beneficial ownership of 5.9% of Capricor Therapeutics Inc.'s common stock as of June 30, 2026.

Summary

• State Street Corporation has filed a Schedule 13G, indicating its beneficial ownership of Capricor Therapeutics Inc. common stock.
• As of June 30, 2026, State Street Corporation beneficially owned 3,397,241 shares, representing 5.9% of the class of securities.
• This filing is made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934.
• State Street Corporation is identified as a holder of investment company securities and acts as an investment adviser.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, primarily reporting a change in beneficial ownership without indicating a significant shift in investment strategy or company performance.

Positives

• State Street Corporation's investment indicates confidence from a major institutional investor in Capricor Therapeutics.
• The 5.9% stake suggests a significant, though not controlling, interest, potentially leading to increased market liquidity and visibility for Capricor's stock.

Negatives

• The filing does not provide specific details on the investment strategy or the rationale behind acquiring this stake.
• The absence of further commentary could imply a passive investment approach rather than active engagement with the company's management.

Risks

• As a Schedule 13G filing, it indicates passive investment, meaning State Street is not seeking to influence or control Capricor's management or policies.
• Changes in beneficial ownership by large institutional investors can sometimes precede or coincide with shifts in market sentiment, though no specific catalyst is mentioned here.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Capricor Therapeutics. It solely reports on the ownership status of State Street Corporation.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that institutional investor filings like this Schedule 13G are common and reflect the ongoing management of investment portfolios. State Street Corporation, through its various subsidiaries like SSGA Funds Management, Inc., is a major global asset manager, and its holdings are closely watched.

Stakeholder Impact

• Shareholders may view the increased institutional ownership as a positive sign of confidence in the company.
• The passive nature of the investment suggests no immediate impact on corporate control or strategic direction from State Street Corporation.

Next Steps

• State Street Corporation will continue to hold or manage its position in Capricor Therapeutics' common stock.
• Future filings will be made if ownership levels change significantly or if investment strategy shifts to a controlling interest.

Key Dates

Keywords

Capricor Therapeutics, State Street Corporation, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Investment Adviser